key: cord-0753526-jqkhumke authors: Chen, Jingsi; Du, Lili; Wang, Feiyang; Shao, Xuan; Wang, Xiaoyi; Yu, Wenzhe; Bi, Shilei; Chen, Dexiong; Pan, Xingfei; Zeng, Shanshan; Huang, Lijun; Liang, Yingyu; Li, Yulian; Chen, Rufang; Xue, Fengwu; Li, Xiuying; Wang, Shouping; Zhuang, Manli; Liu, Mingxing; Lin, Lin; Yan, Hao; He, Fang; Yu, Lin; Jiang, Qingping; Xiong, Zhongtang; Zhang, Lizi; Cao, Bin; Wang, Yan‐Ling; Chen, Dunjin title: Cellular and molecular atlas of the placenta from a COVID‐19 pregnant woman infected at midgestation highlights the defective impacts on foetal health date: 2022-02-09 journal: Cell Prolif DOI: 10.1111/cpr.13204 sha: cf6e1092b21dcf9f40a2667d6604523f37abd8e3 doc_id: 753526 cord_uid: jqkhumke OBJECTIVES: The impacts of the current COVID‐19 pandemic on maternal and foetal health are enormous and of serious concern. However, the influence of SARS‐CoV‐2 infection at early‐to‐mid gestation on maternal and foetal health remains unclear. MATERIALS AND METHODS: Here, we report the follow‐up study of a pregnant woman of her whole infective course of SARS‐CoV‐2, from asymptomatic infection at gestational week 20 to mild and then severe illness state, and finally cured at Week 24. Following caesarean section due to incomplete uterine rupture at Week 28, histological examinations on the placenta and foetal tissues as well as single‐cell RNA sequencing (scRNA‐seq) for the placenta were performed. RESULTS: Compared with the gestational age‐matched control placentas, the placenta from this COVID‐19 case exhibited more syncytial knots and lowered expression of syncytiotrophoblast‐related genes. The scRNA‐seq analysis demonstrated impaired trophoblast differentiation, activation of antiviral and inflammatory CD8 T cells, as well as the tight association of increased inflammatory responses in the placenta with complement over‐activation in macrophages. In addition, levels of several inflammatory factors increased in the placenta and foetal blood. CONCLUSION: These findings illustrate a systematic cellular and molecular signature of placental insufficiency and immune activation at the maternal–foetal interface that may be attributed to SARS‐CoV‐2 infection at the midgestation stage, which highly suggests the extensive care for maternal and foetal outcomes in pregnant women suffering from COVID‐19. Coronavirus disease 2019 (COVID-19), a serious contagious disease caused by novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread to over 200 countries worldwide. Although pregnant women were more susceptible to the coronaviruses and several pregnant women infected with SARS-CoV-2 are reported to have severe adverse outcomes, 1,2 most pregnant women underwent mild or asymptomatic infections without lasting consequences. 3 The potential impact of SARS-CoV-2 infection during pregnancy on maternal and foetal development, regardless of the presence or absence of symptoms, need to be investigated with additional analysis and research. The placenta expresses the receptors for SARS-CoV-2, including ACE2 and TMPRSS2, throughout pregnancy, 4 indicating the potential spread of SARS-CoV-2 via the placenta to the foetus. Some investigations have confirmed transplacental transmission of SARS-CoV-2 at early-to-mid gestation and late gestation using immunohistochemistry, RNA in situ hybridization, or both, for viral antigens or viral nucleic acid in foetal cells of placenta. [5] [6] [7] [8] [9] [10] [11] [12] Histological features such as maternal vascular malperfusion, foetal vascular malperfusion, chronic histiocytic intervillositis or increased intervillous fibrin were found in a small set of placentas from infected women. [13] [14] [15] [16] However, transplacental transmission of the virus is very uncommon and has not been identified in most COVID-19 pregnant cases. 17, 18 It has been well known that a normal functional placenta is an effective barrier to prevent intrauterine vertical transmission of pathogens. Placental factors may be the major reason that so few placentas become infected with SARS-CoV-2. It is, therefore, crucial to uncover the intrinsic defence system and innate immune molecular changes of the placental barrier in COVID-19 pregnant women. Here, we reported a case of a COVID-19 pregnant woman (marked as COVID-RS in the following) infected with SARS-CoV-2 at the 20th week of gestation. We followed up the woman from asymptomatic, mild illness and severe illness to recovery stages until pregnancy termination due to an incomplete uterine rupture at gestational week 28 . Histological analysis of the foetal and placental tissues as well as single-cell transcriptome for the placenta was performed. No intrauterine transmission of SARS-CoV-2 was found in this patient, whereas the cellular and molecular signatures indicate placenta insufficiency and significant antiviral and pro-inflammatory response at the maternal-foetal interface. The findings thus highlight the extensive care for maternal and foetal health in pregnant women suffering from COVID-19, even after timely clinical treatment for the virus infection. The study was approved by the Ethics Committee Medical Ethics Committee at The Third Affiliated Hospital of Guangzhou Medical University (Medical Research No. 2020090 ). Written informed consent for this study was obtained from the enrolled women. Nasopharyngeal and vaginal swabs were collected at admission and during hospitalization to test for SARS-CoV-2. At delivery, maternal blood, umbilical cord blood and foetal blood were collected in EDTA of Medicine, Xiamen University, Xiamen 361102, China. Email: caobin19@xmu.edu.cn tubes. Full-thickness placental biopsies were obtained. In the case of caesarean delivery, amniotic fluid was collected without blood or meconium contamination. Tissue samples from the foetus were collected after death with written informed consent from the pregnant woman. Both biopsies and blood samples were obtained sterilely by a dedicated operator. The demographic characteristics of this COVID-RS case and the gestational age-matched noninfection preterm patients (delivering at 29-31 weeks of gestation because of cervical dysfunction but without any other complications, labelled as CTRL group hereafter) enrolled in this study are displayed in Table S1 . For single-cell RNA-seq, cells from the placenta were isolated by using the previously described protocol. 19 Two preterm placenta samples (details described in Table S1 ) were used as noninfection control. Briefly, placenta tissues were minced, enzymatically digested for 30-40 min using cocktail dissociation solution, treated with DMEM containing 10% FBS and filtered (70-mm nylon filter; Falcon). Resuspended cell pellets were subjected to 1 × Red Blood Cell Removal Solution (Biogems) for 5 min to remove red blood cells and then subjected to be washed twice. After red blood cells lysis and dead cells removing using the Dead Cell Removal Kit (Miltenyi Biotec), cells were counted using an automatic cell counter. Then, viable cells were used for single-cell RNAseq library construction using the Chromium Single Cell 3' kit v2 (10× Genomics), following the manufacturer's instructions. After quantifying the DNA libraries, the single-cell libraries' sequencing was performed using the Illumina Platform (HiSeq X Ten System). 5′ transcriptomic sequencing data were also performed for the COVID-RS placenta. The 3′ and 5′ transcriptomic sequencing data were both analysed as duplication. Samples were sequenced on a Novaseq 6000 with the following run parameters: read 1, 26 cycles; read 2, 98 cycles; and index 1, 8 cycles. A median sequencing depth of 25,000 reads/cell was targeted for each sample. The CellRanger (10XGenomics) analysis pipeline was used to generate a digital gene expression matrix from the sequencing data. For placenta samples, 5′ and 3′ transcriptome sequencing data from the COVID-RS patient and 3' transcriptome sequencing data from 2 CTRL women with the comparable duration of gestational age were analysed. Seurat v.3 was used for downstream analysis. The following criteria were then applied to each cell of all samples: gene number between 200 and 6000 and mitochondrial gene percentage proportion < 0.05. We utilized the R package scDblFinder 20 (version 1.9, https://github.com/plger/ scDbl Finder) to eliminate doublets/multiplets in single-cell sequencing data according to the previous reports. 21, 22 After filtering, a total of 17,481 cells were left for the following analysis. The datasets were integrated using the standard Seurat v3 integration workflow. The graph-based clustering was performed using FindCluster in Seurat v.3. Wilcox in Seurat v.3 (FindAllMarkers function) was used to perform differential gene expression analysis. For each cluster of placenta cells, differentially expressed genes (DEGs) of COVID-RS placenta were generated to compare with the same cell type of the CTRL group. A gene was considered significant with adjusted Bonferroni-adjusted p < 0.05. Gene Ontology (GO) enrichment analyses of differentially expressed genes were implemented by the ClusterProfiler R package. GO terms with corrected p-value < 0.05 were considered significantly enriched by differentially expressed genes. Dot plots were used to visualize enriched terms by the enrichplot R package. To systematically scan for viral RNA in scRNA-seq data, an Unsupervised Viral-Track Pipeline was used 25 (https://github.com/ Pierr eBSC/Viral -Track). For haematoxylin and eosin (HE) staining and immunohistochemistry (IHC), tissue samples were fixed with 10% buffered formalin at room temperature for 6 h. Samples were embedded in paraffin. After routine rehydration and antigen retrieval, 5μm paraffin sections were stained for HE or with the primary antibodies ( Anti-Cytokeratin 7 antibody (Table S2 ). Negative controls were performed by replacing the specific antibody with rabbit or mouse IgG. To quantify nuclear number in STB, three slides per sample were subjected to immunohistochemistry, and the number of nuclei in the STB was counted in five random fields of each slide, presented as nuclear number per square millimetre of villous area. The results were presented as mean ± SD, and statistically analysed by two-tailed t test. Whole lysates from tissues were extracted with RIPA buffer containing protease inhibitor cocktail (Sigma-Aldrich). Protein concentrations were determined using the BCA™ Protein Assay Kit (Pierce). Western blotting was performed as described previously. Antibodies used for Western blotting include ACE2, hCG beta and β-actin (Table S3 ). Inflammation 20-Plex Human ProcartaPlex™ Panel (EPX200-12185-901, Thermo) was used to assess the concentration of cytokines in maternal and foetal plasma and placenta samples from the COVID-RS case and CTRL group according to the manufacturer's protocol via Luminex MAGPIX system (Luminex). The whole process of the infection and treatment of a pregnant COVID-19 case was illustrated in Figure where muscle layer was lacking, and only uterine serosa remained and bulged outward. The foetus weighed 920 g, while died during caesarean delivery due to severe asphyxia. None apparent morphologic abnormality was observed in the foetus, placenta and umbilical cord at delivery. To assay SARS-CoV-2 infection, whole maternal blood, cord blood Histological examinations on the placenta and foetal tissues revealed relatively sparse villi and normal morphology of foetal organs, including the brain, lung, colon, liver and fallopian tube ( Figure S2 ). Using preterm delivery placentas as gestational agematched controls (CTRL; n = 3, details described in Table S1 ), the expressions for Syncytin-2, the marker of trophoblast syncytialization and hCGβ, the classical marker of STB secretory function, were decreased in the placenta of this case relative to the CTRL ( Figure 2A,B ). In addition, the COVID-RS placenta exhibited more syncytial knots ( Figure 2B ,C). These observations indicated an impaired syncytialization process and inflammation response in the COVID-RS placenta. To illustrate the molecular alterations in the maternal-foetal inter- Figure 2F and Figure S3D ). In our single-cell sequencing data sets, 6,187 trophoblasts were identified by the expression of KRT7 and PERP ( Figure S3D ) and We Complement has been well known to promote immune cell activation and the pro-inflammatory states, and complement over-activation is were enriched in macrophages (dM1, dM2 and HB) and monocytes ( Figure 5B ). Immunostaining results validated significant accumulation of the activated C3 deposition in villi and increased C5AR1 intensity in CD68-labelled macrophages in the COVID-RS placenta ( Figure 5C ). Our CellphoneDB analysis showed that complement activation-related ligand/receptor pairs between DS/FB1 and macrophages were significantly increased in the COVID-RS placenta ( Figure 5D ). Here, we reported a whole COVID-19 disease process in a pregnant woman infected with SARS-CoV-2 at the second trimester, covering stages from asymptomatic, mild illness, severe illness, recovery, to pregnant termination due to an incomplete uterine rupture. Recent studies reported that around 13.55%-88% of pregnant women exhibit asymptomatic infection for SARS-CoV-2, 28,29 and 10% of asymptomatic pregnant women have developed to the symptomatic stage. In our study, the woman was admitted into the hospital at the asymptomatic stage, which ensures a well monitor of her disease process and timely treatment, including antiviral medicine and oxygen support, the commonly used therapeutics for COVID-19 pregnancy. It has been reported that pregnant women with severe or critical COVID-19 display a high rate of acute respiratory distress syndrome (ARDS), 30 In this case, we were unable to follow through with the maternal and foetal outcomes until late gestation because the pregnancy was terminated due to uterine rupture caused by a short IPI from the last caesarean section. We also did not find apparent histopathological abnormalities in the foetus from this COVID-RS case, except for a relatively low foetal weight 40 showed that the immune responses in the placenta to viral infection might persist for long periods although the case was recovery. Third, the features of the activated complement system may contribute to triggering the inflammatory response in the COVID-RS placenta. It has been found that most COVID-19 patients with respiratory failure present consistent over-activation of complement system 50 and high expression of C5AR1 receptors in pulmonary myeloid cells. 51 Generally, complement inhibition at the fetomaternal interface is essential for pregnancy success. Here, in the COVID-RS placenta, several complement-associated genes were upregulated in DS and FBs, in parallel with extensive C3 deposition in the placenta and higher expression of C5AR1 receptor in macrophages. The dysregulated complement activation has been indicated in the pathogenesis of pregnancy complications such as preeclampsia and preterm birth. 52 Consistent with the pro-inflammatory status in the placenta, we also found elevation of inflammatory factors, such as MIP-1 beta (CCL4), Canada) for assistance with the language editing during the preparation of this manuscript. There are no competing financial or nonfinancial interests regarding this work. Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study Pregnancy and COVID-19 Single-cell RNA expression profiling of SARS-CoV-2-related ACE2 and TMPRSS2 in human trophectoderm and placenta Fetal and placental infection with SARS-CoV-2 in early pregnancy Detection of SARS-CoV-2 in placental but not fetal tissues in the second trimester SARS-CoV-2 infection of the placenta Persistence of SARS-CoV-2 in the first trimester placenta leading to transplacental transmission and fetal demise from an asymptomatic mother Vertical transmission of SARS-CoV-2 in second trimester associated with severe neonatal pathology Transplacental transmission of SARS-CoV-2 infection Analysis of SARS-CoV-2 vertical transmission during pregnancy Vertical transmission of coronavirus disease 2019: a systematic review and meta-analysis Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infecting pregnant women and the fetus, intrauterine transmission and placental pathology during the Coronavirus Disease 2019 (COVID-19) pandemic: it's complicated Placental pathology of COVID-19 with and without fetal and neonatal infection: trophoblast necrosis and chronic histiocytic intervillositis as risk factors for transplacental transmission of SARS-CoV-2 A structured review of placental morphology and histopathological lesions associated with SARS-CoV-2 infection Maternal respiratory SARS-CoV-2 infection in pregnancy is associated with a robust inflammatory response at the maternal-fetal interface Chronic histiocytic intervillositis with trophoblast necrosis is a risk factor associated with placental infection from Coronavirus Disease 2019 (COVID-19) and intrauterine maternal-fetal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) transmission in live-born and stillborn infants Synthesis and systematic review of reported neonatal SARS-CoV-2 infections Single cell transcriptional signatures of the human placenta in term and preterm parturition Doublet identification in single-cell sequencing data using scDblFinder A cellular census of human lungs identifies novel cell states in health and in asthma Benchmarking computational doublet-detection methods for single-cell RNA sequencing data Cell PhoneDB: inferring cell-cell communication from combined expression of multi-subunit ligand-receptor complexes Inference and analysis of cell-cell communication using Cell Chat Host-viral infection maps reveal signatures of severe COVID-19 patients Expert consensus for managing pregnant women and neonates born to mothers with suspected or confirmed novel coronavirus (COVID-19) infection Complement as a target in COVID-19? Severe acute respiratory syndrome coronavirus 2 in pregnancy: symptomatic pregnant women are only the tip of the iceberg Universal screening for SARS-CoV-2 in women admitted for delivery Clinical course of severe and critical coronavirus disease 2019 in hospitalized pregnancies: a United States cohort study Identification of required host factors for SARS-CoV-2 infection in human cells Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity A Message from the human placenta: structural and immunomodulatory defense against SARS-CoV-2 Mixed signature of activation and dysfunction allows human decidual CD8(+) T cells to provide both tolerance and immunity Gestational stage and IFNlambda signaling regulate ZIKV infection in utero Protective effect of interferon-alpha against cell-mediated human immunodeficiency virus transmission resulting from coculture of infected lymphocytes with fetal trophoblasts Inhibition of SARS-CoV-2 by type I and type III interferons Antiviral activity of type I, II, and III interferons counterbalances ACE2 inducibility and restricts SARS-CoV-2 Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 Gestational age, gender and parity specific centile charts for placental weight for singleton deliveries in Aberdeen Turnover of human villous trophoblast in normal pregnancy: what do we know and what do we need to know? Placental trophoblast syncytialization potentiates macropinocytosis via mTOR signaling to adapt to reduced amino acid supply Defective decidualization during and after severe preeclampsia reveals a possible maternal contribution to the etiology Pre-eclampsia-like syndrome induced by severe COVID-19: a prospective observational study Distinct patterns of IFITMmediated restriction of filoviruses, SARS coronavirus, and influenza A virus IFITM proteins inhibit placental syncytiotrophoblast formation and promote fetal demise The contribution of macrophages to normal and pathological pregnancies IL-1 receptor antagonist therapy mitigates placental dysfunction and perinatal injury following Zika virus infection Severe SARS-CoV-2 placenta infection can impact neonatal outcome in the absence of vertical transmission Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis The complement system and preeclampsia Complement component C5a activates ICAM-1 expression on human choroidal endothelial cells P-selectin drives complement attack on endothelium during intravascular hemolysis in TLR-4/heme-dependent manner Reversing behavioural abnormalities in mice exposed to maternal inflammation Pregnancy and postpartum outcomes in a universally tested population for SARS-CoV-2 in New York City: a prospective cohort study Adverse pregnancy outcomes, maternal complications, and severe illness among US delivery hospitalizations with and without a coronavirus disease 2019 (COVID-19) diagnosis Differential immune responses in pregnant patients recovered from COVID-19 The data sets generated and analysed in the study are available in the Genome Sequence Archive (HRA000830) and can be accessed upon request. All custom scripts can be accessed upon request to the corresponding author. https://orcid.org/0000-0003-4014-6138Yan-Ling Wang https://orcid.org/0000-0002-9448-7803Dunjin Chen https://orcid.org/0000-0002-1839-3469 Additional supporting information may be found in the online version of the article at the publisher's website.